Objective To compare and analyze the application of ultrasound and magnetic resonance ( M R) examination in evaluating the progress of hemophilia arthropathy( HA ) . Methods Forty‐three cases of HA patients treated in our hospital were collected and divided into observation group and control group according to with or without synovial hyperplasia by ultrasonography at the beginning of the observation period . At the beginning and end of the observation period , ultrasound and M R examinations were performed respectively . T wo imaging findings of the target joint were recorded and scored by ultrasound and M R . T wo types of imaging findings were compared and statistically analyzed . Results T here were positive linear correlations between the ultrasonic score and M R score at the beginning and the end of the observation period ( r ＝ 0 .945 ,0 .943 ; all P ＜ 0 .01 ) . However , there were significant differences in hemosiderin deposition and subarticular bone erosion ( all P ＜0 .05) . A t the end of the observation period , the level of synovial thickening ,the degree of cartilage erosion ,the degree of bone erosion ,the score of ultrasonic joint and M R score were significantly higher than those in the observation period , and the difference were statistically significant compared with the control group ( all P ＜0 .05) . T herefore ,synovial membrane hyperplasia can be considered as the key clinical manifestation leading to rapid progress of hemophilia target joint . Ultrasound measurement of synovial thickness ,ultrasonic score and M R score can be used as a method to predict the progress of the target joint disease . T he areas under the ROC curve were 0 .829 ,0 .897 , 0 .894 , and the cut‐off values were 2 .25 mm , 3 .5 score and 3 .5 score , respectively . Conclusions Ultrasound and MR imaging have a good correlation in evaluating HA .Significant synovial thickening of target joint indicates that HA will continue to progress .

ObjectiveTo determine the epidemiological characteristics of COVID-19 in Shaanxi Province. MethodsEpidemiological analysis was conducted on the confirmed cases of COVID-19 （n=245） from January 23rd， 2020 through February 21st， 2020 based on the official data announced by Shaanxi Province. The effects of local population migration， prevention and control measures on the epidemic were explored. ResultsAs of February 21st， 2020， a total of 245 COVID-19 cases had been notified in Shaanxi Province， with a cumulative incidence rate of 0.63 per 100 000， of which imported cases accounted for 47.34%. The high incidence was observed between January 31st and February 5th. Xi’an had the largest number of COVID-19 cases， followed by Ankang， Hanzhong and Xianyang， totally accounting for 81.20% of the cases in the province. In terms of social factors， daily morbidity was positively correlated with Baidu migration scale index 14 days before. On January 25th， the provincial health emergency response was launched， and on January 31st， it was further upgraded for quarantine. On February 20th， the provincial prevention and control system was implemented by classified areas. There were no emerging local cases after February 21st and no confirmed cases for 28th consecutive days as of March 19th. Local cases and close contacts were cleared to zero on March 27th. ConclusionThe COVID-19 epidemic in Shaanxi Province is mainly concentrated in Guanzhong area and southern Shaanxi， with a widespread pattern in all cities. The prevention and control measures have effectively contained the epidemic， with a declining incidence. However， quarantine of suspected cases and close contacts remains crucial for routine prevention and control strategy.

ObjectiveTo observe the clinical course and explore the risk factors for SARS-CoV-2 RNA negative conversion duration （NCD） in asymptomatic and mild-symptomatic patients infected with the SARS-CoV-2 Omicron variant. MethodsClinical data were collected from 244 confirmed cases of corona virus disease （COVID-19） with Omicron variant infection admitted to a temporal makeshift hospital in Shanghai from April 9， 2022 to May 20， 2022. Demographic and clinical data were analyzed， with a primary focus on the time of COVID-19 nucleic acid conversion. Univariate and multivariate Cox regression analysis were used to determine identify risk factors associated with NCD. ResultsThe median duration of negative RNA conversion was 9 days （ranged 7‒12 days）. The percentage of patients with positive nucleic acid results on the 5th， 7th， 10th， and 14th days after confirmed infection was 68.4%， 47.1%， 20.1%， and 5.7%， respectively. Kaplan-Meier curves indicated a median nucleic acid conversion time of 12 days （ranged 10‒14 days） for patients with hypertension， 9 days （ranged 7‒11 days） in patients without hypertension， and 11 days （ranged 9‒13 days） for patients aged ≥60 years， and 9 days （ranged 7‒11 days） for patients aged <60 years. Multivariate Cox regression analysis showed that only hypertension was an independent risk factor of NCD （RR=1.60； 95% CI： 1.03‒2.49， P=0.036）. ConclusionIn asymptomatic or mildly symptomatic patients infected with the Omicron variant， 20.1% patients continue to exhibit positive viral nucleic acid on the 10^th days of infection. The independent risk factor associated with the conversion of SARS-CoV-2 nucleic acid to negative is hypertension.

Objective:To study the real-world outcome of China FDA-approved Sofosbuvir (SOF)/Velpatasvir (VEL) in Northwest China.Methods:In this multicenter, prospective, real-world cohort study, we recruited patients from 10 sites from Northwest China, who were chronically infected with HCV GTs 1-6 from 06/2018 to 09/2019. Patients received SOF (400mg)/VEL (100mg) for 12 weeks, and with ribavirin 900-1200 mg for GT3 cirrhosis and for any genotype decompensated cirrhosis. The primary endpoint was sustained virological response at 12-weeks post-treatment (SVR12) and safety. The secondary endpoint was the change of liver function after the achievement of SVR12.Results:Totally, 143 patients were enrolled in the study, four patients were lost to follow-up and one died during the follow-up, 138 patients were included in per-protocol analysis. Of the 138 patients, the mean age 53 years, 53.6% male, 94.2% Han nationality, 53.6% liver cirrhosis, 10.1% HBsAg +, 6.5% renal dysfunction, 5.1% treatment-experienced, and 16.7% patients received ribavirin treatment. The genotype distribution was as follows: 35.5% GT1, 42.8% GT2, 15.9% GT3, and 5.8% un-typed. The SVR12 rate was 96.5% (138/143, 95% CI: 93.5%-99.6%) for intention-to-treat analysis, and in per-protocol analysis, all 138 patients obtained SVR12 (100%). Compared with baseline, the serum total bilirubin, ALT and AFP levels decreased (all P < 0.05), as well as increased ALB and platelet count (all P < 0.001) at post-treatment 12-weeks. Overall adverse events (AEs) rate is 29.0%, and the most common AEs were anemia (14.5%) and fatigue (8.0%). Severe side effects (edema and fatigue) occurred in 2 patients, one of whom needed a short-term interruption of treatment due to fatigue. Conclusion:In this real-world cohort study, 12-week SOF/VEL regimen with or without ribavirin achieved high SVR12 rates (96.5%-100% overall) with excellent safety profile among patients with HCV GT1/2/3 infection including patients with GT3 and cirrhosis, and led to improvement of liver function.